Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on July 6, 2021, covering events occurring on July 1, 2021. The filing discloses the execution of new employment agreements with three key executive officers: the Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms and separation benefits.
Material Changes and Executive Compensation
Effective July 1, 2021, the Company entered into new employment agreements with the following executives:
- Amy Trombly (CEO): Base salary of $325,000 per annum. Eligible for a target bonus of up to 50% of base salary (up to 120% for exceeding goals) and annual equity grants. Severance includes six months' salary for termination without cause/good reason, or twelve months' salary for change of control. Includes a target annual bonus of $162,500 upon change of control.
- Jerry Dvonch (CFO): Base salary of $200,000 per annum. Eligible for a target bonus of up to 50% of base salary (up to 120% for exceeding goals) and annual equity grants. Severance includes six months' salary for termination without cause/good reason, or twelve months' salary for change of control. Includes a target annual bonus of $100,000 upon change of control.
- Bruce Thornton (COO): Base salary of $250,000 per annum. Eligible for a target bonus of up to 50% of base salary (up to 120% for exceeding goals) and annual equity grants. Severance includes one time base salary for termination without cause, good reason, or change of control. Bonus upon termination is discretionary.
All agreements include provisions for automatic vesting of unvested time-based equity awards upon qualifying termination, COBRA health premium reimbursement, and standard non-compete and confidentiality clauses.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. The primary risk disclosed relates to the financial obligations associated with executive separation benefits, which are contingent upon specific termination events and the execution of a general release of claims.
Key Facts for Investor Verification
- Verify the total annual fixed compensation cost increase resulting from these new agreements compared to prior terms.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific definitions of "good reason" and "change of control."
- Confirm the Company's current cash position to assess its ability to fund potential severance obligations (up to 12 months of salary for CEO/CFO) in the event of a change of control.
- Note that Ms. Trombly continues to bill the Company for legal services through Trombly Business Law, PC, and may represent other clients as an attorney.